Pediatric Clostridium difficile infection (CDI)-related hospitalizations are increasing. We sought to describe the epidemiology of pediatric CDI at a quaternary care hospital.
Nested case-control study within a cohort of children <18 years tested for C. difficile between January and August 2008. The study included patients who were ≥1 year with a positive test and diarrhea; those without diarrhea (ie, presumed colonization) were excluded. Two unmatched controls per case were randomly selected from patients ≥1 year with a negative test. Potential predictors of CDI included age, gender, comorbidities, prior hospitalization, receipt of C. difficile-active antibiotics in the prior 24 hours, and recent (≤4 weeks) exposure to antibiotics or acid-blocking medications. Multivariate logistic regression models were created to identify independent predictors of CDI.
Of 1891 tests performed, 263 (14%) were positive in 181 children. Ninety-five patients ≥1 year with CDI were compared with 238 controls. In multivariate analyses, predictors of CDI included solid organ transplant (odds ratio [OR], 8.09; 95% confidence interval [CI], 2.10–31.12), lack of prior hospitalization (OR, 8.43; 95% CI, 4.39–16.20), presence of gastrostomy or jejunostomy (G or J) tube (OR, 3.32; 95% CI 1.71–6.42), and receipt of fluoroquinolones (OR, 17.04; 95% CI, 5.86–49.54) or nonquinolone antibiotics (OR, 2.23; 95% CI, 1.18–4.20) in the past 4 weeks. Receipt of C. difficile-active antibiotics within 24 hours before testing was associated with a lower odds of CDI (OR, 0.22; 95% CI, 0.09–0.58).
Recent antibiotic exposure and certain comorbid conditions (solid organ transplant, presence of a gastrostomy or jejunostomy tube) were associated with CDI. Diagnostic testing has less utility in patients being treated with C. difficile-active antibiotics.
SUPPLEMENTAL DIGITAL CONTENT IS AVAILABLE IN THE TEXT.
From the *Division of Infectious Diseases, Children's Hospital Boston, Boston, MA; †Departments of Medicine and Laboratory Medicine, Children's Hospital Boston, Boston MA; ‡Harvard Medical School, Boston, MA; §Department of Infection Prevention and Control, Children's Hospital Boston, Boston, MA; ¶RAND Corporation, Boston, MA; and ∥Department of Population Medicine, Center for Child Health Care Studies, Harvard Pilgrim Health Care Institute & Harvard Medical School, Boston, MA.
Accepted for publication December 16, 2010.
Address for correspondence: Thomas J. Sandora, MD, MPH, Division of Infectious Diseases, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115. E-mail: firstname.lastname@example.org.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.pidj.com).